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Background: Long-acting beta-agonists were one of the first-choice bronchodilator agents for stable chronic
obstructive pulmonary disease. But the impact of long-acting beta-agonists on mortality was not well investigated.
Methods: National Emphysema Treatment Trial provided the data. Severe and very severe stable chronic obstructive
pulmonary disease patients who were eligible for volume reduction surgery were recruited at 17 clinical centers in
United States during 1988–2002. We used the 6–10 year follow-up data of patients randomized to non-surgery
treatment. Hazard ratios for death by long-acting beta-agonists were estimated by three models using Cox
proportional hazard analysis and propensity score matching were measured.
Results: The pre-matching cohort was comprised of 591 patients (50.6% were administered long-acting beta-agonists.
Age: 66.6 ± 5.3 year old. Female: 35.4%. Forced expiratory volume in one second (%predicted): 26.7 ± 7.1%. Mortality
during follow-up: 70.2%). Hazard ratio using a multivariate Cox model in the pre-matching cohort was 0.77 (P = 0.010).
Propensity score matching was conducted (C-statics: 0.62. No parameter differed between cohorts). The propensity-
matched cohort was comprised of 492 patients (50.0% were administered long-acting beta-agonists. Age: 66.8 ± 5.1
year old. Female: 34.8%. Forced expiratory volume in one second (%predicted) 26.5 ± 6.8%. Mortality during follow-up:
69.1%). Hazard ratio using a univariate Cox model in the propensity-matched cohort was 0.77 (P = 0.017). Hazard ratio
using a multivariate Cox model in the propensity-matched cohort was 0.76 (P = 0.011).
Conclusions: Long-acting beta-agonists reduce mortality of severe and very severe chronic obstructive pulmonary
disease patients.
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Long-acting beta-agonists (LABA), one of the first-choice
bronchodilator agents for stable chronic obstructive
pulmonary disease (COPD) [1] improve obstruction,
hyperinflation, quality of life, dyspnea, frequency of
exacerbation, and frequency of rescue medication [2-6].
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reproduction in any medium, provided the orother parameters were often used as surrogate endpoints
to evaluate the effect of agents, because it is often difficult
to observe sufficient deaths in feasible studies. Considering
favorable outcomes about surrogate endpoints, it is
reasonable to hypothesize that LABA improve life prognosis
of stable COPD patients. However these surrogate
endpoints do not always reflect mortality of respiratory
disease with airflow obstruction. One famous example
is beta-agonist for bronchial asthma. The beta-agonists
improve airflow obstruction, dyspnea, and quality of life of
bronchial asthma patients. However, the regular use of
inhaled beta-agonist increasing the number of deaths ortd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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whether LABA actually reduce the mortality of COPD
patients is an important question despite the repeatedly
proven association between lung function, quality of life,
and LABA administration for COPD patients.
In 2007, Calverley et al conducted a large-scale random-
ized controlled trial spanning 3 years, involving 6112
patients, in which mortality as secondary endpoint was
compared between placebo- and LABA-administrated
cohorts [3]. However, their study showed no significant
reduction in mortality, and the authors concluded that the
study was not an accurate reflection of the mortality
because of high withdrawal rate and fewer observed
deaths than anticipated.
Therefore, in this study, we evaluated the life prognosis of
patients treated with LABA in a cohort with prospectively
collected data using Cox hazard model and propensity
score matching method.
Methods
The data set previously collected for the National
Emphysema Treatment Trial (NETT) [8] was provided
by the National Heart, Lung, and Blood Institute. The
current study was approved by the Yokohama City
Hospital Institutional Review Board. The need for informed
consent was waived for this study due to patient anonymity
and the observational nature of the study.
We calculated the hazard ratios (HRs) for death from
LABA administration in three Cox proportional hazards
models. In Model 1, we evaluated the HR using a multi-
variate Cox model in the pre-matching cohort. Propensity
score matching was performed before the analyses for
Models 2 and 3. In Model 2, we estimated the HR using a
univariate Cox model in a propensity-matched cohort. In
Model 3, we evaluated the HR using a multivariate Cox
model in the propensity-matched cohort. Our primary
outcome was death, evaluated as HR in the three models
(Figure 1, Table 1).
Patient selection
The major entry criteria for the NETT study were as
follows: radiographic evidence of bilateral emphy-
sema; forced expiratory volume in one second (FEV1)
(%predicted) ≤ 45%; a pressure of oxygen in artery
(PaO2) ≥ 45 mmHg; a pressure of carbon dioxide in
artery (PaCO2) ≤ 60 mmHg; 6-minute walking distance ≥
140 m; participation in pulmonary rehabilitation; not at
high risk for perioperative morbidity or mortality; suitable
for lung volume reduction surgery; and likeliness to
completing the trial. From January 1998 to July 2002,
3777 patients were evaluated in 17 clinical centers; of
the 1218 patients eligible for enrollment, 610 and 608 were
randomly allocated to the medical and surgical cohorts
respectively. The inclusion criteria are described inmore detail in the previous report [8]. We used the data
of only medical cohort patients in this study. Among the
610 patients, patients who lacked data for age (N = 15),
hemoglobin (N = 1), or diffusing capacity of the lung for
carbon monoxide (DLCO) (N = 3) were excluded. The
remaining 591 patients comprised the pre-matching cohort
and the propensity-matched 492 patients comprised the
propensity-matched cohort (Figure 1). A patient who was or
was not prescribed LABA at randomization (= 0 months)
was considered a LABA(+) or LABA(−) patient.
Treatments
The primary care physicians provided the following treat-
ment in close compliance with the guideline [9]: smoking
cessation, regular inhaled bronchodilators, oxygen therapy,
immunization, pulmonary rehabilitation, and additional
measures including oral corticosteroids [8].
Measurements
Spirometric data were collected after administering bron-
chodilators. The DLCO was adjusted for hemoglobin:
DLCO × hemoglobin/0.0697. PaO2 and PaCO2 were mea-
sured in ambient air even if patients were administered
long-term oxygen therapy (LTOT). The cutoff value for an
emphysematous change on CT was −950 Hounsfield. The
peak pulmonary arterial pressure was measured using right
heart catheterization or an echocardiography. The peak
pulmonary arterial pressure measured by echocardiography
was estimated as follows: mean right atrial pressure + 4 ×
(estimated tricuspid peak systolic velocity)^2. Recent
emergency hospital stay included both admission and
overstay in the hospital. “Recent” emergency visit and
“recent” hospital stay indicated events during the last
three months were asked on pre-observational data acqui-
sition. Death was defined as death due to all causes, not
just respiratory-related deaths. Additional information
about the measurement method is provided previously [8].
LABA prescription during the follow-up
We checked whether the patients were administered
LABA or not at 6, 12, 24, 46, 48 and 60 months. This was
evaluated only for interpretation of endpoints (i.e., the
intention-to-treat principle).
Statistics
The Chi-square test (with Yates’ correction, if necessary),
the Wilcoxon rank sum test, the Cox proportional hazard
analysis, Kaplan-Meier analysis, and the logrank test were
used where appropriate. Propensity score matching is a
matching technique to balance several variables at once by
predicting the probability that each patient receive some
intervention or not. The most important advantage of
propensity score matching over classical matching is that
this method can balance much more variables efficiently,
Figure 1 Flow chart for patient entry. LABA: Long-acting beta-agonist. NETT: National emphysema treatment trial.
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more than 10 parameters due to deficit of cases. Detailed
methodology for this matching is provided in other article
[10]. We used three different models and believe that the
consistency among the models enhances the validity of
study results [11,12] (Table 1). Propensity score matching
was performed to balance 26 independent variables. The
pre-matching cohort was divided into five subgroups
according to the propensity score and the maximum
number of matches possible was made in each subgroup
with computer-based randomization [10]. Each LABA
(+) patient was matched with one LABA (−) patient.
The quality of matching was evaluated by comparing pa-
tient characteristics between cohorts. The area of emphy-
sematous change (%) and peak pulmonary arterial
pressure were used only for comparison between LABA
(+) and LABA (−) cohorts and not for multivariate ana-
lysis as data for some patients were not available.
Forced vital capacity (FVC) (mL), FEV1 (mL), and
FEV1/FVC (%) were also excluded from multivariateTable 1 Comparison of three independent models
Model 1 2 3
Propensity score matched? No Yes Yes
Any difference between cohorts? Yes (not much) No No
Single- or multi-variable analysis? Multi- Single- Multi-
Number of patients 591 492 492analysis to avoid possible multicolinearity with FVC (%
predicted) and/or FEV1 (%predicted).
Results and discussion
Pre-matching cohort
The background characteristics of the 591 patients in
the pre-matching cohort are summarized in Table 2. In
general, cohorts of 292 LABA (−) patients and 299
LABA (+) patients had similar characteristics except for
short-acting beta-agonist administration. In the pre-
matching cohort, 176 patients survived for the observation
period, and the duration until censoring was 94.7 ± 14.4
(range 70.1–123.9) months. Throughout the observation
period, ≥ 65% of LABA (+) and (−) patients were treated
with the initially classified treatments (Figure 2).
Model 1
The stepwise multivariable Cox model analysis which
initially included LABA and 26 other covariables as
independent variables was performed in the pre-matching
cohort. Eleven independent variables remained in the last
model. The HR for death due to LABA use was 0.77
(95% CI: 0.64–0.94; P = 0.010) (Figure 3).
Propensity score matched cohort
Logistic regression analysis was performed for propensity
matching. Only non-administration of short-acting beta-
agonist (P = 0.039) and decreased PaCO2 level (P = 0.007)
Table 2 Baseline characteristics of patients (pre-matching cohort)
All patients Comparison of LABA (+) and (−) cohorts
LABA (−) LABA (+) P
N 591 292 299
Age (year) 66.6 ± 5.3 66.9 ± 5.2 66.4 ± 5.3 0.208
Sex (female) 209 (35.4%) 93 (31.8%) 116 (38.8%) 0.074
Race (not white) 33 (5.6%) 20 (6.8%) 13.0 (4.3%) 0.185
Annual income < 30000 $ 304 (51.4%) 155 (53.1%) 149 (49.8%) 0.429
FEV1 (%predicted) 26.7 ± 7.1 26.8 ± 7.1 26.7 ± 7.0 0.780
FEV1 (mL) 777 ± 240 782 ± 237 772 ± 243 0.456
FEV1/FVC (%) 31.2 ± 6.3 30.9 ± 6.0 31.5 ± 6.6 0.358
FVC (%predicted) 67.2 ± 15.1 68.0 ± 15.3 66.5 ± 14.9 0.346
FVC (mL) 2545 ± 782 2582 ± 772 2509 ± 791 0.225
Forced residual capacity (mL) 6042 ± 1311 6111 ± 1323 5975 ± 1298 0.243
Hb adjusted DLCO 8.1 ± 3.1 8.1 ± 3.0 8.0 ± 3.1 0.761
Peak pulmonary arterial pressure (mmHg) 33.7 ± 6.2 (N = 502) 34.2 ± 6.1 (N = 252) 33.3 ± 6.3 (N = 250) 0.110
Hemoglobin (g/dL) 14.4 ±1.3 14.4 ± 1.2 14.3 ± 1.3 0.905
PaO2 (mmHg) 64.2 ± 10.0 64.0 ±10.0 64.4 ± 10.0 0.838
PaCO2 (mmHg) 43.1 ± 5.8 43.6 ± 6.1 42.6 ± 5.4 0.083
Area of emphysema (%) 16.1 ± 10.6 (N = 532) 15.7 ± 11.1 (N = 259) 16.4 ± 10.2 (N = 273) 0.228
Body mass index (kg/m^2) 24.7 ± 3.5 24.7 ± 3.6 24.8 ± 3.5 0.503
Six-minute walk distance 368 ± 96 366 ± 95 370 ± 98 0.562
St. George respiratory questionnaire 53.6 ± 12.7 54.1 ± 12.6 53.1 ± 12.7 0.394
Shortness of breath questionnaire 63.3 ± 18.5 63.8 ± 18.1 62.7 ± 18.9 0.483
Beck depression inventory 9.3 ± 5.9 9.2 ± 5.8 9.3 ± 5.9 0.650
Recent emergency visit 75 (12.7%) 38 (13.0%) 37 (12.4%) 0.816
Recent hospital stay 48 (8.1%) 26 (8.9%) 22 (7.4%) 0.492
LTOT during sleep 414 (70.1%) 206 (70.5%) 208 (69.6%) 0.794
LTOT on exertion 465 (78.7%) 233 (79.8%) 232 (77.6%) 0.513
Oral corticoid 153 (25.9%) 76 (26.0%) 77 (25.8%) 0.939
Inhaled corticosteroid 447 (75.6%) 211 (72.3%) 236 (78.9%) 0.059
Short-acting beta-agonist 515 (87.1%) 264 (90.4%) 251 (83.9%) 0.019
Anticholinergic agent 486 (82.2%) 242 (82.9%) 244 (81.6%) 0.686
Theophylline 238 (40.3%) 124 (42.5%) 114 (38.1%) 0.282
Diuretics 86 (14.6%) 41 (14.0%) 45 (15.1%) 0.728
Parameters were compared with Wilcoxon rank sum test or Chi-square test.
LABA: long-acting beta-agonist.
FEV1: forced expiratory volume in one second.
FVC: forced vital capacity.
Hb adjusted DLCO: hemoglobin adjusted diffusing capacity of the lung for carbon monoxide.
PaO2: pressure of oxygen in artery.
PaCO2: pressure of carbon dioxide in artery.
LTOT: long-term oxygen therapy.
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in this model. The mean propensity scores among
LABA (−) and LABA (+) patients were 0.48 ± 0.11 and
0.53 ± 0.11, respectively. The C-statistic was 0.62. The
pre-matching cohort was divided into five subgroups on
the basis of the propensity score. Among the fivesubgroups, 246 LABA(+) patients were matched with
246 LABA(−) patients. There was no significant difference
between the cohorts (Table 3). Throughout the obser-
vation period, ≥ 63% of LABA(+) and > 70% of LABA
(−) patients were treated with the initially classified
treatments (Figure 2).
Figure 2 Prescription of LABA (long-acting beta-agonist) during follow-up. On 0 month, there were 292 LABA (−) patients and 299 LABA (+)
patients in the pre-matching cohort; and 246 LABA (−) patients and 246 LABA (+) patients in the propensity matched cohort.
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In the propensity-matched cohort, univariate Cox model
analysis produced HR for death from LABA of 0.77 (95%
CI: 0.62–0.96; P = 0.018) (Figure 3). The Kaplan-Meier
curve showed that LABA(+) patients had better life
prognosis than LABA (−) patients (P = 0.016, Logrank test)
(Figure 4).
Model 3
The stepwise multivariable Cox model analysis, which
initially included LABA and 26 other co-variables as
independent variables, was performed in the propensity-
matched cohort. Eleven independent variables remainedFigure 3 Hazard ratio by long-acting beta-agonists for death.in the last model. The HR for death by LABA was 0.76
(95%CI: 0.61–0.94; P = 0.011) (Figure 4).
Discussion
To our knowledge, this is the first study demonstrating
that LABA reduce mortality of COPD patients. Although
the reason for this mortality reduction is unclear, LABA
may prevent further deterioration of conditions by
reducing the frequency of exacerbation, and may prevent
pulmonary hypertension and cor pulmonale by improving
lung functions [2-6].
Our results are not in complete agreement with those
of the well-designed large-scale randomized controlled
trial by Calverley [3]. A few possible reasons for this
discrepancy are as follows: (i) Calverley observed 231
deaths (15.2%) among 1524 placebo patients and 205
deaths (13.5%) among1521 salmeterol patients, whereas
in our pre-matching cohort, we observed 222 deaths
(76.0%) among 292 LABA (−) patients and 193 deaths
(64.5%) among 299 LABA (+) patients. Although our
cohort is smaller than that in the Calverley’s study, the
higher mortality enabled us to observe similar numbers
of deaths. The higher mortality is mainly supported by
the two reasons: FEV1(%predicted) was 44% ± 12% in the
Calverley’s and 27% ± 7% in ours; Calverley’s included data
of 3 years, whereas the mean observational duration for
survivors was 7.9 years in ours.(ii) Statistical power in our
study is also supported by higher “compliance” to the
classified protocol. At the 36th month, less than 32% of
LABA (−) patients were administered LABA and less than
25% of the LABA (+) patients were not administered
LABA. Contrarily, withdrawal rate in placebo cohort in
Calverley’s study was 44% after three years. Some
Table 3 Comparison of LABA (+) and LABA (−) patients in
the propensity-matched cohort
LABA (−) LABA (+)
N 246 246 P
Age (year) 66.7 ± 5.0 66.8 ± 5.3 0.732
Sex (female) 86 (35.0%) 85 (34.6%) 0.925
Race (not white) 10 (4.1%) 12 (4.9%) 0.663
Annual income < 30000 $ 125 (50.8%) 123 (50.0%) 0.857
FEV1 (%predicted) 26.5 ± 6.8 26.6 ± 6.8 0.991
[FEV1 (mL)] 766 ± 222 777 ± 242 0.866
[FEV1/FVC (%)] 31.0 ± 6.0 31.2 ± 6.3 0.926
FVC (%predicted) 67.1 ± 15.4 67.0 ± 15.0 0.849
[FVC (mL)] 2527 ± 757 2556 ± 802 0.772
Forced residual capacity (mL) 6072 ± 1330 6040 ± 1306 0.842
Hb adjusted DLCO 7.9 ± 2.9 8.1 ± 3.2 0.632
[Peak pulmonary arterial pressure
(mmHg)]
34.0 ± 6.0 33.3 ± 6.2 0.202
Hemoglobin (g/dL) 14.4 ± 1.2 14.4 ± 1.3 0.626
PaO2 (mmHg) 64.2 ± 10.0 64.2 ± 10.2 0.829
PaCO2 (mmHg) 43.1 ± 5.8 43.0 ± 5.4 0.972
[Area of emphysema (%)] 16.3 ± 11.1 16.0 ± 9.5 0.759
Body mass index (kg/m^2) 24.7 ± 3.5 24.7 ± 3.6 0.860
Six-minute walk distance (m) 366 ± 93 371 ± 98 0.577
St. George respiratory questionnaire 53.4 ± 12.5 53.3 ± 12.6 0.974
Shortness of breath questionnaire 63.0 ± 17.9 63.0 ± 19.0 0.961
Beck depression inventory 9.1 ± 5.8 9.0 ± 5.8 0.988
Recent emergency visit 33 (13.4%) 30 (12.2%) 0.686
Recent hospital stay 19 (7.7%) 17 (6.9%) 0.729
LTOT during sleep 173 (70.3%) 170 (69.1%) 0.769
LTOT on exertion 191 (77.6%) 191 (77.6%) 1.000
Oral corticoid 70 (28.5%) 62 (25.2%) 0.416
Inhaled corticosteroid 186 (75.6%) 186 (75.6%) 1.000
Short-acting beta-agonist 219 (89.0%) 217 (88.2%) 0.777
Anticholinergic agent 205 (83.3%) 203 (82.5%) 0.811
Theophylline 103 (41.9%) 94 (38.2%) 0.408
Diuretics 34 (13.8%) 38 (15.4%) 0.610
[parameters]: parameters not used in logistic regression analysis for propensity
score matching were shown in brackets.
Parameters were compared with Wilcoxon rank sum test or Chi-square test.
FEV1: forced expiratory volume in one second.
FVC: forced vital capacity.
Hb adjusted DLCO: hemoglobin adjusted diffusing capacity of the lung for
carbon monoxide.
PaO2: pressure of oxygen in artery.
PaCO2: pressure of carbon dioxide in artery.
LTOT: long-term oxygen therapy.
Figure 4 Kaplan meier curve for survival (Model 2).
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study and concluded that salmeterol was associated with
decreased mortality with relative risk of 0.83 (P = 0.004),
which is compatible with our study [13,14].The results of the meta-analysis of Salpeter et al in
2006 conflict with our result [15]. They reported that 21
(1.6%) of 1320 beta-agonist administered patients had
respiratory-related death, which is significantly higher
than mortality of 0.7% (8 of 1084) among beta-agonist
non-administered patients. Only 1.2% of patients in the
meta-analysis died, partly because the observation period
was as short as 3 to 12 months and because respiratory-
related death (not all-cause death) was adopted as an
endpoint in their study. COPD patients often died from
cardiovascular disease, which was perhaps exacerbated by
systemic inflammation or cor pulmonale [16]. All-cause
death, not just respiratory death, is desirable for evalua-
ting deaths due to co-morbidities. Furthermore, 19 of 29
deaths in the meta-analysis were observed in one unpub-
lished study. If Calverley’s large scale study in 2007 [3] had
also been included in this meta-analysis, the results would
have favored beta-agonist administration.
Our study has several limitations. First, this was an
observational study and not a randomized controlled trial.
Since the current guideline [1] recommends administering
LABA, a randomized controlled trial was not thought to
be a feasible. Our study design was a reasonable choice to
evaluate the effect of LABA among severe and very severe
COPD patients. Second, our study involved “post-treat-
ment variables.” For propensity matching, covariates had
better be evaluated before the dependent variable. This
implies that the physician should have decided whether or
not to start LABA after all parameters were measured.
However, this assumption was not fully satisfied in this
study. LABA administered before pre-observational data
acquisition affects baseline characteristics in this study. If
the patients previously received LABA treatment, it is
likely that the improvement or deterioration in their
condition already occurred at the time of pre-observational
data acquisition. The LABA (+) and (−) cohorts in the
propensity-matched cohort were equal (Table 3) at pre-
observational data acquisition because of cancellation of
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matching. This bias impaired the observed effect of LABA
and increased beta error. Though, we observed significant
HR. Third, the type of LABA is not clearly identified in our
study, because NETT database groups all LABAs in a single
category. Only salmeterol was approved in the United
States on the beginning of this study. Formoterol and
arformoterol were additionally approved in 2001 and
2006. Considering market share during 1998-2008,
salmeterol, which is often prescribed as fluticasone/
salmeterol combination, was prescribed for most of the
patients; and formoterol or arformoterol were prescribed
for small portion of patients. Recently used once daily
indacaterol was not approved until 2011, which is after
end of data collection of this study. Fourth, our cohort
contained only patients with FEV1 (%predicted) ≤ 45%
and this study did not clarify if LABA improves the life
prognosis of COPD patients with FEV1 (%predicted) > 45.
However, we still believe LABA have favorable effects on
mild and moderate COPD patients, because LABA improve
obstruction, hyperinflation, quality of life, dyspnea, fre-
quency of exacerbation, and frequency of rescue medi-
cation among mild and moderate COPD patients [2-6],
and because LABA reduce mortality among severe and
very severe COPD patients as shown in this study. Fifth,
about 30% of patients were “deviated” from the initial
treatment after 3 years (Figure 2). But we do not think
these deviations are not serious problem, because
these treatment deviation cause bias to distract the dif-
ference of observed mortality, i.e. HR getting closer to
1.0. Nonetheless, our study find out statistically and
clinically significant difference among LABA (+) and
LABA (−) patients. Lastly, we cannot evaluate respiratory-
related mortality, because data about cause of death was
not provided.
Conclusion
We demonstrated that LABAs, mostly salmeterol, reduce
death among severe and very severe COPD patients with
a HR of 0.76–0.77.
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